Comprehensive Understanding and Evolutional Therapeutic Schemes for Pseudomyxoma Peritonei: A Literature Review. (14th May 2022)

• Record Type: Journal Article
• Authors: Ye, Suiting; Zheng, Song
• Is Part Of: American journal of clinical oncology. Volume 45:Number 5(2022)
• Page Start: 223
• Page End: 231
• Publication Date: 2022-05-14
• Subjects: pseudomyxoma peritonei -- hyperthermic intraperitoneal chemotherapy -- cytoreductive surgery -- recurrence -- treatment -- prognosis; Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0000000000000911
• Languages: English
• ISSNs: 0277-3732

Abstract

Abstract : Pseudomyxoma peritonei is an infrequent solid tumor in clinical practice. The low morbidity and deficient understanding of this mucus-secreting malignant disease increase the risks of delayed identification or uncontrollable deterioration. In quite a lot cases, patients go through complete cytoreduction surgery and hyperthermic intraperitoneal chemotherapy could receive a long time survival over 5 years. But the recurrence rate is also hard to overlook. Unlike other types of cancer, the standard treatment for this considerable groups has not been confirmed yet. With the advanced medical progression, studies have been carrying out based on pathogenesis, biological characters, and mutated gene location. All but a few get statistical survival benefits, let alone the breaking progress on research or therapeutic practice in the field. We try to give a comprehensive exposition of pseudomyxoma peritonei around the epidemiology, radiologic features, clinical manifestation, present treatment and promising schemes, hoping to arise much attention and reflection on the feasible solutions, especially for the recrudescent part.